CN113573724B - 重组润滑素和组合物以及其使用方法 - Google Patents

重组润滑素和组合物以及其使用方法

Info

Publication number
CN113573724B
CN113573724B CN202080021544.XA CN202080021544A CN113573724B CN 113573724 B CN113573724 B CN 113573724B CN 202080021544 A CN202080021544 A CN 202080021544A CN 113573724 B CN113573724 B CN 113573724B
Authority
CN
China
Prior art keywords
cells
mucin
cell
muc1
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080021544.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN113573724A (zh
Inventor
M·帕塞克
H·里辛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CN113573724A publication Critical patent/CN113573724A/zh
Application granted granted Critical
Publication of CN113573724B publication Critical patent/CN113573724B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
    • A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
    • A61L12/14—Organic compounds not covered by groups A61L12/10 or A61L12/12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
    • A61L2101/32—Organic compounds
    • A61L2101/46—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080021544.XA 2019-01-15 2020-01-15 重组润滑素和组合物以及其使用方法 Active CN113573724B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962792660P 2019-01-15 2019-01-15
US62/792,660 2019-01-15
PCT/US2020/013752 WO2020150396A1 (en) 2019-01-15 2020-01-15 Recombinant lubricins, and compositions and methods for using the same

Publications (2)

Publication Number Publication Date
CN113573724A CN113573724A (zh) 2021-10-29
CN113573724B true CN113573724B (zh) 2025-12-19

Family

ID=71614494

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080021544.XA Active CN113573724B (zh) 2019-01-15 2020-01-15 重组润滑素和组合物以及其使用方法
CN202080021615.6A Pending CN113905753A (zh) 2019-01-15 2020-01-15 重组粘蛋白和组合物以及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080021615.6A Pending CN113905753A (zh) 2019-01-15 2020-01-15 重组粘蛋白和组合物以及其使用方法

Country Status (5)

Country Link
US (2) US20220127319A1 (https=)
EP (1) EP3911355A4 (https=)
JP (1) JP7667569B2 (https=)
CN (2) CN113573724B (https=)
WO (2) WO2020150390A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109735434B (zh) * 2016-09-14 2022-09-23 四川蓝光英诺生物科技股份有限公司 人工组织前体及制备其的方法
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法
CN114107437A (zh) * 2021-11-30 2022-03-01 南通大学 一种基于荧光素酶亚基互补的主蛋白酶抑制剂活性检测系统及在药物筛选中的应用
CN115144303B (zh) * 2022-08-01 2025-05-16 中国科学院自动化研究所 基于磁粒子布朗弛豫的细胞质粘度检测方法及应用
CN117106024B (zh) * 2022-10-21 2024-05-24 南京市妇幼保健院 一种人血清多肽agdmp1及其在改善胰岛素抵抗中的应用
WO2025166171A1 (en) * 2024-01-31 2025-08-07 Cornell University Manufacturing and bioprocessing of multispecies biolubricants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867350A (zh) * 2003-08-14 2006-11-22 惠氏公司 重组润滑素分子及其用途
CN113905753A (zh) * 2019-01-15 2022-01-07 康奈尔大学 重组粘蛋白和组合物以及其使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
CA2618791C (en) * 2005-08-12 2014-05-13 Riken Novel mucin-type glycoprotein and use thereof
WO2008133928A2 (en) * 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication
ES2634505T3 (es) * 2009-08-13 2017-09-28 Lubris Llc Tratamiento de PRG4 para la cistitis intersticial
US20140187474A1 (en) * 2011-02-16 2014-07-03 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic use of mucin glycans
WO2013151665A2 (en) * 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US20150010606A1 (en) * 2013-07-08 2015-01-08 Arthrex, Inc. Intra-articular injection and implant attachment of molecule consisting of lubricin and extracellular superoxide dismutase or hyaluronic acid and extracellular superoxide dismutase
US20180125926A1 (en) * 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
AU2014354859B2 (en) * 2013-11-26 2020-04-09 Lubris Llc Compositions and methods for inhibiting intercellular interactions
AU2016211694B2 (en) * 2015-01-26 2021-11-11 Lubris Llc Use of PRG4 as an anti-inflammatory agent
US20160280767A1 (en) * 2015-03-23 2016-09-29 Lonza Ltd. Methods for controlling protein glycosylation
WO2016187414A1 (en) * 2015-05-19 2016-11-24 Lubris Llc Use of prg4 to improve dynamic visual acuity and higher order aberrations
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
RU2771490C2 (ru) * 2016-01-13 2022-05-05 Мериал, Инк. Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
WO2017165674A1 (en) * 2016-03-23 2017-09-28 International Aids Vaccine Initiative Immunogenic trimers
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
CN109055426B (zh) * 2018-08-06 2021-06-25 智享生物(苏州)有限公司 一种在中华仓鼠卵巢细胞中表达生产类人润滑素的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867350A (zh) * 2003-08-14 2006-11-22 惠氏公司 重组润滑素分子及其用途
CN102924584A (zh) * 2003-08-14 2013-02-13 惠氏公司 重组润滑素分子及其用途
CN113905753A (zh) * 2019-01-15 2022-01-07 康奈尔大学 重组粘蛋白和组合物以及其使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Articular Cartilage Superficial Zone Protein (SZP) Is Homologous to Megakaryocyte Stimulating Factor Precursor and Is a Multifunctional Proteoglycan with Potential Growth-Promoting, Cytoprotective, and Lubricating Properties in Cartilage Metabolism;Carl R.Flannery等，;Biochemical and Biophysical Research Communications;19990127;第254卷;摘要及图1 *
Carolyn R. Shurer 等.Stable recombinant production of codon-scrambled lubricin and mucin in human cells.Biotechnology and Bioengineering.2019,图1、第2.2、2.4节. *
Q92954.PRG4_HUMAN;EMBL DataBase;EMBL DataBase;20180328;Sequence & Isoforms 部分 *
Stable recombinant production of codon-scrambled lubricin and mucin in human cells;Carolyn R. Shurer 等;Biotechnology and Bioengineering;20190501;图1、第2.2、2.4节 *

Also Published As

Publication number Publication date
US20220127319A1 (en) 2022-04-28
CN113573724A (zh) 2021-10-29
JP7667569B2 (ja) 2025-04-23
CN113905753A (zh) 2022-01-07
US12304934B2 (en) 2025-05-20
JP2022522965A (ja) 2022-04-21
EP3911355A1 (en) 2021-11-24
EP3911355A4 (en) 2022-06-01
WO2020150390A1 (en) 2020-07-23
US20220127318A1 (en) 2022-04-28
WO2020150396A1 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
CN113573724B (zh) 重组润滑素和组合物以及其使用方法
Shurer et al. Physical principles of membrane shape regulation by the glycocalyx
JP5801293B2 (ja) 血清アミロイドｐ誘導体並びに同誘導体の製造及び使用
US9322036B2 (en) Methods and compositions for inactivating alpha 1,6 fucosyltransferase (FUT8) gene expression
Pan et al. Sequence-specific mucins for glycocalyx engineering
Seifried et al. Glycoprotein mimics with tunable functionalization through global amino acid substitution and copper click chemistry
Beckwith et al. Calorimetric analysis of the interplay between synthetic Tn antigen-presenting MUC1 glycopeptides and human macrophage galactose-type lectin
Hütte et al. A bacterial mannose binding lectin as a tool for the enrichment of C-and O-mannosylated peptides
Littlechild et al. Keratan sulfate phenotype in the β-1, 3-N-acetylglucosaminyltransferase-7–null mouse cornea
Mullerova et al. Lactose-functionalized carbosilane glycodendrimers are highly potent multivalent ligands for Galectin-9 binding: Increased glycan affinity to galectins correlates with aggregation behavior
Flowers et al. Deciphering isomers with a multiple reaction monitoring method for the complete detectable O-glycan repertoire of the candidate therapeutic, lubricin
Wang et al. Surface shave: revealing the apical-restricted uroglycome
Flowers et al. Core-2 O-glycans are required for galectin-3 interaction with the osteoarthritis related protein lubricin
EP3728286B1 (en) Engineered o-glycosylation in recombinant polypeptides and uses thereof
Shurer The Biophysical Role of the Cellular Glycocalyx: Engineering Glycoproteins to Control Cell-Surface Properties
Gao Chemoenzymatic Synthesis of Heparan Sulfate Proteoglycan and Mimetics
Moon Understanding the Roles of Posttranslational Modifications in Aggregation Using Synthetic Proteins
HK1139988A (en) Methods and compositions for inactivating alpha 1,6 fucosyltransferase (fut 8) gene expression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant